熱門資訊> 正文

NewAmsterdam Pharma报告财年业绩

2026-02-19 04:25

NewAmsterdam Pharma press release (NAMS): FY Revenue of $22.5M.
Net loss for the year ended December 31, 2025, was $203.8 million, compared to net loss of $241.6 million in the year ended December 31, 2024.
As of December 31, 2025, NewAmsterdam reported cash, cash equivalents and marketable securities of $728.9 million, compared to $834.2 million as of December 31, 2024.

More on NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Seeking Alpha’s Quant Rating on NewAmsterdam Pharma
Historical earnings data for NewAmsterdam Pharma
Financial information for NewAmsterdam Pharma

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。